The combination therapy of CD4+ iTregs and CD8+ iTregs may provide a new way to solve the problem because the GVL effect can be preserved by CD8+ iTregs, and CD4+ iTregs function to attenuate GVHD in the meanwhile, which achieves the effect of one plus one being greater than two (81). Here, CD8A is linked to graft versus host disease.